1. Signaling Pathways
  2. Immunology/Inflammation
  3. Galectin

Galectin

Galectins comprise a family of soluble β-galactoside binding proteins, which regulate key biological processes including cell growth, differentiation, apoptosis, and immune responses.

Sixteen galectin genes have been identified in animal kingdoms, 12 of which are expressed in humans. Galectins are usually classified into three groups based on their structure: (i) prototypical galectins (galectin-1 (Gal1), Gal2, Gal5, Gal7, Gal10, Gal11, Gal 13, Gal14, and Gal15), characterized by a single CRD, which can act as monomers or form homodimers; (ii) the chimeric galectin Gal3 (the only member of this class), with a single CRD and a large amino-terminal domain that facilitates the formation of oligomers; (iii) the tandem repeat galectins, with two CRDs that are linked through a small peptide domain; this group includes Gal4, Gal6, Gal8, Gal9, and Gal12. Recently, Galectins have been implicated as major therapeutic determinants that confer sensitivity or resistance to a wide range of anticancer modalities including chemotherapy, radiotherapy, targeted therapies, antiangiogenic therapies, and immunotherapies.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W340234
    4,5-Dibromo-2-pyrrolic acid
    99.34%
    4,5-Dibromo-2-pyrrolic acid (compound 2) is an immunosuppressive compound. 4,5-Dibromo-2-pyrrolic acid suppresses the proliferative response of splenocytes to suboptimal concentrations of the mitogen, concanavalin A (Con A).
    4,5-Dibromo-2-pyrrolic acid
  • HY-155191
    Galectin-3/galectin-8-IN-1
    Inhibitor 99.53%
    Galectin-3/galectin-8-IN-1 (Compound 53) is a dual Galectin-3 and galectin-8 C-terminal domain inhibitor, with Kd values of 4.12 μM and 6.04 μM respectively. Galectin-3/galectin-8-IN-1 inhibits the MRC-5 lung fibroblast cells migration. Galectin-3/galectin-8-IN-1 can be used for research of cancer and tissue fibrosis.
    Galectin-3/galectin-8-IN-1
  • HY-170510
    GB2095
    Inhibitor 98.92%
    GB2095 is an orally active and selective galectin-3 inhibitor. GB2095 shows superior selectivity for both human (KD = 0.036 μM) and mouse galectin-3 (KD = 0.35 μM) over other galectins (such as h-Gal-1/4N/4C/8N/8C/9N/9C and m-galectin-1). GB2095 inhibits tumor growth in syngeneic mouse models of breast and melanoma cancers. GB2095 can be used for breast and melanoma cancer research.
    GB2095
  • HY-P1592
    G3-C12
    99.64%
    G3-C12 is a galectin-3 binding peptide, with Kd of 88 nM, and shows anticancer activity.
    G3-C12
  • HY-144312
    Thiobis-β-Galactose-propyne
    Inhibitor 99.76%
    Thiobis-β-Galactose-propyne is an effective multivalent galectin-3 (Gal-3) inhibitor. Galectin-3 is involved in many metabolism processes related to cancer. Galectin-3-IN-1 is a click chemistry reagent. It contains an alkyne group that can undergo a copper-catalyzed azide-alkyne cycloaddition (CuAAc) reaction with molecules that have an azide group.
    Thiobis-β-Galactose-propyne
  • HY-P10010
    DB21, Galectin-1 Antagonist
    Inhibitor
    DB21, Galectin-1 Antagonist is a dibenzofuran conjugated peptidomimetic that acts as an allosteric inhibitor of galectin-1 (GAL1)binding to cell surface glycans. DB21, Galectin-1 Antagonis increases inhibition of angiogenesis and tumour growth in melanoma, lung adenocarcinoma and ovarian cancer models.
    DB21, Galectin-1 Antagonist
  • HY-163121
    PST3.1a
    Inhibitor
    PST3.1a is an orally active and brain-penetrant N-acetylglucosamine glycosyltransferase (MGAT5) inhibitor with a human IC50 of 2 µM. PST3.1a inhibits TGFβR and FAK signaling pathway activity. PST3.1a alters β1,6-GlcNAc N-glycans and microtubule/microfilament integrity, increases OLIG2 expression, and inhibits proliferation, migration, invasiveness, and clonogenic capacities of glioblastoma initiating cells. PST3.1a reduces invasive and proliferative capacity of glioblastoma initiating cells in orthotopic graft models, increases overall survival of orthotopic graft model mice. PST3.1a blunts MGAT5 overexpression, decreases renal fibrosis via collagen 1, collagen 4, and galectin 3 downregulation in a rat chronic kidney disease model. PST3.1a can be used for the research of glioblastoma multiforme and chronic kidney disease.
    PST3.1a
  • HY-P1592A
    G3-C12 TFA
    99.44%
    G3-C12 (TFA) is a galectin-3 binding peptide, with Kd of 88 nM, and shows anticancer activity.
    G3-C12 TFA
  • HY-147041A
    (2S)-Selvigaltin
    Inhibitor 99.46%
    (2S)-Selvigaltin is the S-enantiomer of Selvigaltin (HY-147041). Selvigaltin is an orally active galectin-3 (Gal-3) inhibitor.
    (2S)-Selvigaltin
  • HY-163082
    GB1490
    Inhibitor 98.48%
    GB1490 is an orally active galectin inhibitor with Kd values of 0.4 μM and 2.7 μM for galectin-1 and galectin-3, respectively.
    GB1490
  • HY-126854R
    N-Acetyllactosamine (Standard)
    Inhibitor
    N-Acetyllactosamine (Standard) is the analytical standard of N-Acetyllactosamine. This product is intended for research and analytical applications. N-Acetyllactosamine (N-Acetyl-D-lactosamine), a nitrogen-containing disaccharide, is a galectin-3 inhibitor, which is an important component of various oligosaccharides such as glycoproteins and sialyl Lewis X. N-Acetyllactosamine can be used as the starting material for the synthesis of various oligosaccharides. N-Acetyllactosamine has prebiotic effects[1][2][3][4].
    N-Acetyllactosamine (Standard)
  • HY-157821
    Galectin-4-IN-3
    Inhibitor
    Galectin-4-IN-3 (Compound 11) is a Galectin 4C inhibitor, with a Kd of 160 μM.
    Galectin-4-IN-3
  • HY-155192
    Galectin-3/galectin-8-IN-2
    Inhibitor
    Galectin-3/galectin-8-IN-2 (Compound 57) is a dual Galectin-3 and galectin-8 C-terminal domain inhibitor, with Kd values of 12.8 μM and 2.06 μM respectively. Galectin-3/galectin-8-IN-2 inhibits the MRC-5 lung fibroblast cells migration. Galectin-3/galectin-8-IN-2 can be used for research of cancer and tissue fibrosis.
    Galectin-3/galectin-8-IN-2
  • HY-157822
    Galectin-8-IN-2
    Inhibitor
    Galectin-8-IN-2 (Compound 10) is a galectin-8N inhibitor.
    Galectin-8-IN-2
  • HY-170543
    Dual Galectin-3/EGFR-IN-1
    Inhibitor
    Dual Galectin-3/EGFR-IN-1 (Compound 29) is the dual inhibitor for Galectin-3 and EGFR with the KD of 52.29 μM and 3.31 μM. Dual Galectin-3/EGFR-IN-1 inhibits TGF-β-induced hepatic stellate cell (HSCs) activation, induces apoptosis in LX-2 cell, and exhibits anti-liver fibrotic efficacy.
    Dual Galectin-3/EGFR-IN-1
  • HY-139831
    Galectin-8-IN-1
    Galectin-8-IN-1 is a selective ligand for the galectin-8 N-terminal domain (galectin-8N), with a Kd of 48 μM and 15-fold selectivity over galectin-3 and even better selectivity over the other mammalian galectins.
    Galectin-8-IN-1
  • HY-157820
    Galectin-4-IN-2
    Inhibitor
    Galectin-4-IN-2 (compound 12) is an inhibitor of galectin 4C with a galectin dissociation constant of 1.6 mM.
    Galectin-4-IN-2
  • HY-183582
    GB1841
    Inhibitor
    GB1841 is an orally active and selective galectin inhibitor with human galectin-1 Kd of 0.027 μM, human galectin-3 Kd of 0.14 μM, mouse galectin-1 Kd of 0.034 μM and mouse galectin-3 Kd of 1.170 μM. GB1841 can be used for the research of lung cancer.
    GB1841
  • HY-147865
    Apoptosis inducer 8
    Inhibitor
    Apoptosis inducer 8 (Compound 7c) is a galectin-1 (gal-1) mediated apoptosis-inducing agent against global major leading lung cancer burden. Apoptosis inducer 8 significantly reduced the gal-1 protein level. Apoptosis inducer 8 is also a PET imaging agent.
    Apoptosis inducer 8
  • HY-163407
    Galectin-3-IN-4
    Inhibitor
    Galectin-3-IN-4 (compound 5) is a carboxamide analog. Galectin-3-IN-4 is a potent, selective, and orally bioavailable inhibitor of human and mouse galectin-3, with IC50 values of 21 and 167 nM for hGal-3 and mGal-3, respectively. Galectin-3-IN-4 has IC50 values of 1580 and 2750 nM for hGal-1 and hGal-9, respectively.
    Galectin-3-IN-4
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.